Larimar Therapeutics (LRMR) Amortization of Deferred Charges (2015 - 2016)

Larimar Therapeutics (LRMR) posted Amortization of Deferred Charges of $10000.0 for Q4 2016, up 11.11% on a QoQ basis from $9000.0 in Q3 2016, and down 28.57% year-over-year from $14000.0 in Q1 2016.

Larimar Therapeutics (LRMR) Amortization of Deferred Charges (2015 - 2016) Analysis & Trends

Larimar Therapeutics' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $10000.0 for Q4 2016.

  • Quarterly Amortization of Deferred Charges fell 28.57% year-over-year to $10000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $43000.0 (down 30.65% YoY) and the FY2016 annual result came in at $43000.0, down 30.65% from the prior year.
  • Amortization of Deferred Charges was $10000.0 for Q4 2016 at Larimar Therapeutics, up from $9000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $17000.0 in Q2 2015 and bottomed at $9000.0 in Q3 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Larimar Therapeutics 37.00 Mn -99.85 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2016 10,000.00
Dec 31, 2016 10,000.00
Sep 30, 2016 9,000.00
Sep 30, 2016 9,000.00
Jun 30, 2016 11,000.00
Jun 30, 2016 11,000.00
Mar 31, 2016 13,000.00
Mar 31, 2016 13,000.00
Dec 31, 2015 14,000.00
Dec 31, 2015 14,000.00
Sep 30, 2015 15,000.00
Sep 30, 2015 15,000.00
Jun 30, 2015 17,000.00
Jun 30, 2015 17,000.00
Mar 31, 2015 16,000.00
Mar 31, 2015 16,000.00